1
Clinical Trials associated with Hepatitis B Vaccine Delivered Trans-dermally by MAP(Quad Medicine) / Not yet recruitingPhase 1IIT A Phase I, Randomized, Open-Label, Active-Control Study to Evaluate Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Delivered Trans-dermally by Microneedle Array Patch (MAP) in Healthy Adults
This is Phase I, randomized, open-label, active-controlled study to evaluate the safety, tolerability, and immunogenicity of a hepatitis B vaccine administered trans-dermally via microneedle array patch (MAP) compared to the intra-muscular (IM) hepatitis B vaccine (Euvax B™), administered at Day (D) 0, Week (W) 4, W26 among healthy adults aged 19 to 40 years in the Republic of Korea.
100 Clinical Results associated with Hepatitis B Vaccine Delivered Trans-dermally by MAP(Quad Medicine)
100 Translational Medicine associated with Hepatitis B Vaccine Delivered Trans-dermally by MAP(Quad Medicine)
100 Patents (Medical) associated with Hepatitis B Vaccine Delivered Trans-dermally by MAP(Quad Medicine)
100 Deals associated with Hepatitis B Vaccine Delivered Trans-dermally by MAP(Quad Medicine)